Abstract
Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Current Neuropharmacology
Title: Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice
Volume: 9 Issue: 1
Author(s): Shinya Kasai, Hideko Yamamoto, Etsuko Kamegaya, George R. Uhl, Ichiro Sora, Masahiko Watanabe and Kazutaka Ikeda
Affiliation:
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Abstract: Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Export Options
About this article
Cite this article as:
Kasai Shinya, Yamamoto Hideko, Kamegaya Etsuko, R. Uhl George, Sora Ichiro, Watanabe Masahiko and Ikeda Kazutaka, Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016921
DOI https://dx.doi.org/10.2174/157015911795016921 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Orexins/Hypocretins: Pain Regulation and Cellular Actions
Current Pharmaceutical Design Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry Psychotherapy, Suicide and Depression, Body Dysmorphic Disorder, Aggression, an Unusual Case, and the Case for Harm Reduction in Treating Adolescent Substance Abuse
Adolescent Psychiatry Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Organic Synthesis Using Environmentally Benign Acid Catalysis
Current Organic Synthesis Comparison of Two Naloxone Regimens in Opioid-dependent Methadoneoverdosed Patients: A Clinical Trial Study
Current Clinical Pharmacology Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Problematic Internet Use, Sleep Quality and Academic Achievement In Turkish University Students
Adolescent Psychiatry PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease
CNS & Neurological Disorders - Drug Targets Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Current Pharmaceutical Design Marijuana Use in Young Adults: What Do We Know?
Current Psychopharmacology The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder
Current Psychiatry Reviews